Corbis

Corbus Pharmaceuticals is a clinical-stage precision oncology company focused on developing innovative therapies for cancer and metabolic diseases. The company's lead program, CRB-701, is a next-generation antibody-drug conjugate (ADC) targeting Nectin-4, currently being evaluated in Phase 1 trials for solid tumors. Corbus is also advancing CRB-601, an anti-integrin αvβ8 monoclonal antibody designed to enhance anti-tumor immune responses. Additionally, the company is exploring the potential of CRB-913, a peripherally restricted cannabinoid receptor 1 (CB1) inverse agonist, for the treatment of obesity and related metabolic disorders. By leveraging its expertise in immunology and receptor biology, Corbus aims to address significant unmet needs in high-impact therapeutic areas.